Barclays Downgrades Regenxbio to Equal-Weight, Maintains Price Target to $12
Benzinga Newsdesk 2 months ago
NewsDowngradesAnalyst RatingsPrice Target
Barclays analyst Eliana Merle downgrades Regenxbio (NASDAQ:RGNX) from Overweight to Equal-Weight and maintains the price target from $12 to $12.
Barclays analyst Eliana Merle downgrades Regenxbio (NASDAQ:RGNX) from Overweight to Equal-Weight and maintains the price target from $12 to $12.